Auxira Health Secures $7.8M for Virtual Cardiology Platform
Auxira Health’s $7.8 million round was led by Route 66 Ventures and Abundant Venture Partners…
Auxira Health’s $7.8 million round was led by Route 66 Ventures and Abundant Venture Partners and included participation from DigiTx Partners, American Heart Association Ventures, Ensemble Innovation Ventures and City Light Capital. The post Auxira Health Secures $7.8M for Virtual Cardiology Platform appeared first on MedCity News.
Hundred Health emerged from stealth with an app that pulls together users’ medical records, lab results, wearable data and lifestyle information to create personalized, evidence-based 100-day health plans. The post Hundred Health Emerges from Stealth to Turn Health Data into Daily Action appeared first on MedCity News.
Dr. Prajnan Das, department chair of Gastrointestinal (GI) Radiation Oncology at MD Anderson Cancer Center, talks about how precision medicine has evolved and how AI may actually be the technology that supercharges the conversion of the knowledge about human biology to personalized treatments that work. The post How Precision Medicine and AI are Evolving: An…
By GEORGE BEAUREGARD How A.I. could have personalized my 2005 cancer journey I don’t think I’m in the minority of Baby Boomer physicians when it comes to my curiosity and ambivalence about the progressing application of A.I. in medicine. But that curiosity isn’t just prospective, it’s retrospective too. In 2005, I became an outlier who…
The additions would help earlier diagnosis and treatment for affected children
There is no excerpt because this is a protected post.
Pediatric neurosurgeon P. David Adelson, M.D., discusses partnership with Sephos AI on Autonomous Registry and Analytics (AURA) platform
This policy watch provides an overview of recent changes to federal vaccine recommendations in the U.S. and what they mean for insurance coverage.
FDA approval for Enhertu as a first-line breast cancer treatment is important because many patients with HER2-positive cancer do not live long enough to receive a second line of therapy. In Enhertu’s pivotal study in this setting, the HER2-targeting ADC helped patients live more than three years without disease progression or death. The post AstraZeneca,…
This analysis examines how people of color fare compared to White people across 64 measures of health, health care, and social determinants of health using the most recent data available from federal surveys and administrative sets as well as the 2023 KFF Survey on Racism, Discrimination, and Health.